Clinical study of the efficacy of cell-based immunotherapy for malignant tumors (Observational study)

Clinical study of the efficacy of cell-based immunotherapy for malignant tumors (Observational study) - Observational study of the efficacy of cell-based cancer immunotherapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019367

Enrollment

Registered

2015-10-16

Start date

2011-09-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All classes of malignant tumors, for which cell-based immunotherapy was performed in the Center for Advanced Medical Innovation, Kyushu University.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with malignant tumors, for whom cell-based immunotherapy has been performed in our center, and who would agree with entering into this observational study.

Exclusion criteria

Exclusion criteria: Patients to be excluded would satisfy any of the following conditions: (1) patients for whom the standard therapies have not been finished. (2) age under 20 years old (3) T cell- or NK cell-originated leukemia/lymphoma (4) serum positive for HTLV-1 and/or HIV antibody for lymphokine-activated killer cell therapy, or serum positive for HIV antibody for dendritic cell-based vaccine therapy (5) patients of whom prognosis to be estimated at less than three months. (6) Inward patients (7) Patients to be or wishing for pregnancy, or breast-feeding (8) Patients who are regarded as inadequate for study enrollment by the investigator

Design outcomes

Primary

Measure	Time frame
Overall survival period (OS) for each class of malignant tumors	—

Secondary

Measure	Time frame
Progression-free survival period (PFS), Disease-free survival period (DFS), response rate, efficience rate, disease control rate, side effetcs etc for each class of malignant tumors	—

Countries

Japan

Contacts

Public ContactShigeo Takaishi

Center for Advanced Medical Innovation, Kyushu University Division of Advanced Cell Therapy

takaishi@kuhp.kyoto-u.ac.jp092-642-4538

Outcome results